Chastre A, Hafler DA, O’Connor KC. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. N Engl J Med. 2016 14;374(15):1495-6.
However, considerable interest has been raised by a study showing the presence of serum autoantibodies to KIR4.1, an astrocytic inward-rectifying potassium channel, in 47% of adult patients with multiple sclerosis but not in patients with other neurologic diseases or in healthy controls.
On study tested the original method used with 141 pwMS and 131 controls and got nothing interesting.
In the other study a commonality among the studies that have contradicted the original report is that one of the three approaches that were originally used to measure the autoantibodies, a protein antigen–based ELISA, was not used.
How come two papers arise at the same time, either they were talking to each other after one showed the data and the other said hey we have the same data, or maybe one was reviewing the other and said hey we have the same data. However two more agreements and the original data seems more and more on thin ice.